Interestingly, in mut1- and mut2-expressing cells, nuclear accumulation of PY-STAT1 was only partially blocked, an observation that correlates with the attenuated phenotype observed in the reporter gene assay

Interestingly, in mut1- and mut2-expressing cells, nuclear accumulation of PY-STAT1 was only partially blocked, an observation that correlates with the attenuated phenotype observed in the reporter gene assay. humans and nonhuman primates, with human fatality rates of up to 90% (16). Currently, you will find no licensed vaccines or approved treatments available for filovirus infections. Ebolavirus counteracts synthesis of alpha/beta interferon (IFN-/) USL311 and cellular responses to IFN-// (7,8,10,11,23). VP35 blocks production of IFN-/ by inhibiting the activation of interferon regulatory factors by blocking interferon regulatory factor 3 (IRF-3) kinases IKKepsilon and TBK-1 (1,2,21) and by increasing SUMOylation of IRF-7 (3). VP24 impairs cellular responses to IFN-// by blocking nuclear accumulation of tyrosine-phosphorylated STAT1 (PY-STAT1). Nuclear translocation of PY-STAT1 is essential for transcriptional activation of numerous IFN-responsive genes and occurs through conversation with karyopherin -1 (KPN1) and perhaps other members of the NPI-1 subfamily of KPN proteins (14,15,18,19,22,25). Correspondingly, VP24 interacts with the KPN proteins that mediate PY-STAT1 nuclear accumulation (23,24). Other pathogenic viruses also impair innate immune signaling via conversation with KPN proteins, suggesting that this may be a common immune evasion strategy. For example, the severe acute respiratory syndrome coronavirus (SARS-CoV) ORF6 protein tethers a karyopherin -2/karyopherin complex to the endoplasmic reticulum (ER)/Golgi membrane to prevent PY-STAT1 nuclear import complex formation (6), and Hantaan computer virus nucleocapsid protein inhibits NF-B activation through conversation with KPN (26). Our previous work suggests that the conversation of VP24 with select KPN proteins is responsible for the ability of VP24 to inhibit IFN signaling (23,24). In this study, mutations that impair VP24 inhibition of IFN-induced gene expression were recognized. Plasmids expressing USL311 wild-type or mutated VP24 proteins were cotransfected into 293T cells USL311 together with plasmids expressingRenillaluciferase (expressed from a constitutive cytomegalovirus [CMV] promoter) and firefly luciferase (expressed from an IFN-inducible USL311 ISG54 promoter). At 1 day posttransfection, the cells were treated with 1,000 U/ml of human IFN- (PBL Interferon Source) for 16 h, and then cells were lysed and luciferase levels were quantified. Firefly luciferase levels were normalized toRenillaluciferase levels. By using this assay to screen the activity of amino-terminal truncation mutants, we found that deletion of amino acids 1 to 26 of VP24 did not significantly affect the ability of VP24 to inhibit IFN–induced gene expression. However, mutants with larger deletions, encompassing residues 1 to 50, lost the ability to efficiently inhibit IFN–induced gene expression (Fig.1A). This pointed to residues 26 to 50 as important for VP24 function. Alanine-scanning mutagenesis of clusters of 5 amino acids from position 25 to position 50 was performed, and this restricted the effect to residues 36 to 45 (data not shown). Alanine-scanning mutagenesis of this region was then performed and recognized residue 42 as critical for inhibition of the reporter gene expression (Fig.1B). Specifically, a W42A VP24 mutant (mut1) inhibited ISG54 reporter activation to 30% relative to the level for the empty-vector, IFN–treated sample, whereas wild-type VP24 almost completely inhibited reporter expression (Fig.1C and D). == FIG. 1. == VP24 mutants with impaired inhibition of IFN–induced gene expression. At 24 h posttransfection, 293T cells were mock treated or treated with 1,000 U/ml IFN- for 16 h. Cells were then lysed, and lysates were assessed for firefly luciferase activity using a dual luciferase assay (Promega). All reporter gene assays were performed in triplicate (A, B, and D). (A) Inhibition of an ISG54 promoter-driven firefly luciferase gene by Z-VP24 and VP24 truncation mutants. 293T cells were transfected with plasmids pRLTK and pISG54FFluc plus either pCAGGS-empty, -HAVP24, -HAVP24(26-251), -HAVP24(51-251), -HAVP24(61-251), or -HAVP24(71-251). (B) Inhibition of an ISG54 promoter-driven firefly luciferase gene by Z-VP24 and VP24 single alanine mutants. 293T cells were transfected with plasmids pRLTK and pISG54FFluc plus either pCAGGS-empty; Z-VP24; or VP24-Q36A, -G47A, -W38A, -K39A, -V40A, -Y41A, Rabbit Polyclonal to EHHADH -W42A, -G44A, or -I45A. (C) Schematic representation and nomenclature of VP24 mutants. Amino acid 42 and amino acids 142 to 146 of Z-VP24 were replaced with alanine residues to produce VP24 mutants mut1 and mut2, respectively. Mutant VP24 proteins made up of both mut1 and mut2 substitutions were designated mut3. (D) Inhibition of an ISG54 promoter-driven firefly luciferase gene by Z-VP24 and VP24 mutants. 293T cells were transfected with plasmids pRLTK and pISG54FFluc plus either pCAGGS-empty, -HA-Z-VP24, -HAmut1, -HAmut2, or -HAmut3..